AAPL331.34-1.74 (-0.52%) ▼|ABBV263.04+1.27 (+0.49%) ▲|ABT102.03-1.06 (-1.03%) ▼|ACN193.40-1.60 (-0.82%) ▼|ADBE257.76-7.84 (-2.95%) ▼|AMAT421.17-3.04 (-0.72%) ▼|AMD504.20+10.79 (+2.19%) ▲|AMGN375.65-5.85 (-1.53%) ▼|AMT177.71+0.77 (+0.44%) ▲|AMZN248.42-5.12 (-2.02%) ▼|AVGO339.27-5.45 (-1.58%) ▼|AXP324.43-3.35 (-1.02%) ▼|BA209.69-0.58 (-0.28%) ▼|BAC59.52+0.05 (+0.08%) ▲|BKNG171.32-4.03 (-2.30%) ▼|BLK1,058.66-6.94 (-0.65%) ▼|BMY63.73-0.37 (-0.58%) ▼|BNY154.67-2.99 (-1.90%) ▼|BRK-B516.76+1.81 (+0.35%) ▲|C136.17-0.01 (-0.01%) ▼|CAT783.54-0.46 (-0.06%) ▼|CL87.00-0.89 (-1.01%) ▼|CMCSA24.42-0.46 (-1.85%) ▼|COF206.85+0.17 (+0.08%) ▲|COP141.22+4.55 (+3.33%) ▲|COST901.35-17.56 (-1.91%) ▼|CRM255.65-3.78 (-1.46%) ▼|CSCO110.07+0.01 (+0.01%) ▲|CVS94.49-1.06 (-1.11%) ▼|CVX217.77+5.60 (+2.64%) ▲|DE684.04+2.58 (+0.38%) ▲|DHR209.36+6.11 (+3.01%) ▲|DIS106.42-2.17 (-2.00%) ▼|DUK117.77-1.25 (-1.05%) ▼|EMR147.00-1.30 (-0.88%) ▼|FDX308.26-4.31 (-1.38%) ▼|GD358.60+1.79 (+0.50%) ▲|GE307.05-10.51 (-3.31%) ▼|GEV882.81+8.05 (+0.92%) ▲|GILD146.30+0.71 (+0.49%) ▲|GM85.37-1.79 (-2.05%) ▼|GOOG341.43-4.28 (-1.24%) ▼|GOOGL344.98-4.41 (-1.26%) ▼|GS976.67-11.78 (-1.19%) ▼|HD305.48-5.39 (-1.73%) ▼|HON203.44+2.06 (+1.02%) ▲|IBM248.37-0.72 (-0.29%) ▼|INTC97.14-0.05 (-0.05%) ▼|INTU329.27-9.88 (-2.91%) ▼|ISRG377.16-0.78 (-0.21%) ▼|JNJ267.20+0.88 (+0.33%) ▲|JPM352.49+2.36 (+0.67%) ▲|KO88.71-0.11 (-0.12%) ▼|LIN462.96-1.45 (-0.31%) ▼|LLY1,136.11-2.17 (-0.19%) ▼|LMT533.46+4.08 (+0.77%) ▲|LOW194.61-3.56 (-1.80%) ▼|LRCX270.87-2.62 (-0.96%) ▼|MA573.27-1.15 (-0.20%) ▼|MCD252.78-4.71 (-1.83%) ▼|MDLZ62.10-0.29 (-0.46%) ▼|MDT93.75-0.05 (-0.05%) ▼|META670.24+4.64 (+0.70%) ▲|MMM164.67+2.65 (+1.64%) ▲|MO69.81+0.31 (+0.45%) ▲|MRK143.79-0.21 (-0.15%) ▼|MS206.28-0.30 (-0.15%) ▼|MSFT497.12-8.29 (-1.64%) ▼|MU927.60+3.57 (+0.39%) ▲|NEE81.07-0.56 (-0.69%) ▼|NFLX77.90-2.42 (-3.01%) ▼|NKE36.22-0.83 (-2.24%) ▼|NOW141.90-0.45 (-0.32%) ▼|NVDA212.17+1.21 (+0.57%) ▲|ORCL140.35-4.44 (-3.07%) ▼|PEP135.50-0.84 (-0.62%) ▼|PFE27.55-0.17 (-0.61%) ▼|PG146.67+0.54 (+0.37%) ▲|PLTR172.56-0.75 (-0.43%) ▼|PM194.11-0.75 (-0.38%) ▼|QCOM187.80+7.65 (+4.25%) ▲|RTX195.50+0.16 (+0.08%) ▲|SBUX96.58-2.49 (-2.51%) ▼|SCHW107.79+0.48 (+0.45%) ▲|SO85.95-1.05 (-1.21%) ▼|SPG204.10-0.87 (-0.42%) ▼|T26.72+0.21 (+0.79%) ▲|TMO641.39+28.24 (+4.61%) ▲|TMUS180.47-2.43 (-1.33%) ▼|TSLA356.58-2.39 (-0.67%) ▼|TXN263.43+0.01 (+0.00%) ▲|UBER71.43-1.20 (-1.65%) ▼|UNH375.93-7.62 (-1.99%) ▼|UNP283.99-1.09 (-0.38%) ▼|UPS102.35-0.11 (-0.11%) ▼|USB62.22-0.46 (-0.73%) ▼|V375.62+0.34 (+0.09%) ▲|VZ51.45+0.16 (+0.31%) ▲|WFC89.72+1.01 (+1.14%) ▲|WMT108.09-0.99 (-0.91%) ▼|XOM169.32+4.24 (+2.57%) ▲|AAPL331.34-1.74 (-0.52%) ▼|ABBV263.04+1.27 (+0.49%) ▲|ABT102.03-1.06 (-1.03%) ▼|ACN193.40-1.60 (-0.82%) ▼|ADBE257.76-7.84 (-2.95%) ▼|AMAT421.17-3.04 (-0.72%) ▼|AMD504.20+10.79 (+2.19%) ▲|AMGN375.65-5.85 (-1.53%) ▼|AMT177.71+0.77 (+0.44%) ▲|AMZN248.42-5.12 (-2.02%) ▼|AVGO339.27-5.45 (-1.58%) ▼|AXP324.43-3.35 (-1.02%) ▼|BA209.69-0.58 (-0.28%) ▼|BAC59.52+0.05 (+0.08%) ▲|BKNG171.32-4.03 (-2.30%) ▼|BLK1,058.66-6.94 (-0.65%) ▼|BMY63.73-0.37 (-0.58%) ▼|BNY154.67-2.99 (-1.90%) ▼|BRK-B516.76+1.81 (+0.35%) ▲|C136.17-0.01 (-0.01%) ▼|CAT783.54-0.46 (-0.06%) ▼|CL87.00-0.89 (-1.01%) ▼|CMCSA24.42-0.46 (-1.85%) ▼|COF206.85+0.17 (+0.08%) ▲|COP141.22+4.55 (+3.33%) ▲|COST901.35-17.56 (-1.91%) ▼|CRM255.65-3.78 (-1.46%) ▼|CSCO110.07+0.01 (+0.01%) ▲|CVS94.49-1.06 (-1.11%) ▼|CVX217.77+5.60 (+2.64%) ▲|DE684.04+2.58 (+0.38%) ▲|DHR209.36+6.11 (+3.01%) ▲|DIS106.42-2.17 (-2.00%) ▼|DUK117.77-1.25 (-1.05%) ▼|EMR147.00-1.30 (-0.88%) ▼|FDX308.26-4.31 (-1.38%) ▼|GD358.60+1.79 (+0.50%) ▲|GE307.05-10.51 (-3.31%) ▼|GEV882.81+8.05 (+0.92%) ▲|GILD146.30+0.71 (+0.49%) ▲|GM85.37-1.79 (-2.05%) ▼|GOOG341.43-4.28 (-1.24%) ▼|GOOGL344.98-4.41 (-1.26%) ▼|GS976.67-11.78 (-1.19%) ▼|HD305.48-5.39 (-1.73%) ▼|HON203.44+2.06 (+1.02%) ▲|IBM248.37-0.72 (-0.29%) ▼|INTC97.14-0.05 (-0.05%) ▼|INTU329.27-9.88 (-2.91%) ▼|ISRG377.16-0.78 (-0.21%) ▼|JNJ267.20+0.88 (+0.33%) ▲|JPM352.49+2.36 (+0.67%) ▲|KO88.71-0.11 (-0.12%) ▼|LIN462.96-1.45 (-0.31%) ▼|LLY1,136.11-2.17 (-0.19%) ▼|LMT533.46+4.08 (+0.77%) ▲|LOW194.61-3.56 (-1.80%) ▼|LRCX270.87-2.62 (-0.96%) ▼|MA573.27-1.15 (-0.20%) ▼|MCD252.78-4.71 (-1.83%) ▼|MDLZ62.10-0.29 (-0.46%) ▼|MDT93.75-0.05 (-0.05%) ▼|META670.24+4.64 (+0.70%) ▲|MMM164.67+2.65 (+1.64%) ▲|MO69.81+0.31 (+0.45%) ▲|MRK143.79-0.21 (-0.15%) ▼|MS206.28-0.30 (-0.15%) ▼|MSFT497.12-8.29 (-1.64%) ▼|MU927.60+3.57 (+0.39%) ▲|NEE81.07-0.56 (-0.69%) ▼|NFLX77.90-2.42 (-3.01%) ▼|NKE36.22-0.83 (-2.24%) ▼|NOW141.90-0.45 (-0.32%) ▼|NVDA212.17+1.21 (+0.57%) ▲|ORCL140.35-4.44 (-3.07%) ▼|PEP135.50-0.84 (-0.62%) ▼|PFE27.55-0.17 (-0.61%) ▼|PG146.67+0.54 (+0.37%) ▲|PLTR172.56-0.75 (-0.43%) ▼|PM194.11-0.75 (-0.38%) ▼|QCOM187.80+7.65 (+4.25%) ▲|RTX195.50+0.16 (+0.08%) ▲|SBUX96.58-2.49 (-2.51%) ▼|SCHW107.79+0.48 (+0.45%) ▲|SO85.95-1.05 (-1.21%) ▼|SPG204.10-0.87 (-0.42%) ▼|T26.72+0.21 (+0.79%) ▲|TMO641.39+28.24 (+4.61%) ▲|TMUS180.47-2.43 (-1.33%) ▼|TSLA356.58-2.39 (-0.67%) ▼|TXN263.43+0.01 (+0.00%) ▲|UBER71.43-1.20 (-1.65%) ▼|UNH375.93-7.62 (-1.99%) ▼|UNP283.99-1.09 (-0.38%) ▼|UPS102.35-0.11 (-0.11%) ▼|USB62.22-0.46 (-0.73%) ▼|V375.62+0.34 (+0.09%) ▲|VZ51.45+0.16 (+0.31%) ▲|WFC89.72+1.01 (+1.14%) ▲|WMT108.09-0.99 (-0.91%) ▼|XOM169.32+4.24 (+2.57%) ▲|
18.7 C
New York
Wednesday, September 16, 2026

Tag: 6

newssourceFORcompanyinformationcontent1releasesmarket

Disclosure of notification received from Alychlo

Regulated information
Nazareth (Belgium)/Rotterdam (The Netherlands), 18 July 2025 – 6 PM CET

European Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN

– EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children (≥2 years) with NF1-PN, a rare genetic disorder with debilitating symptoms – 
– EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children (≥2 years) with NF1-PN, a rare genetic disorder with debilitating symptoms –

European Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN

– EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children (≥2 years) with NF1-PN, a rare genetic disorder with debilitating symptoms – 
– EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children (≥2 years) with NF1-PN, a rare genetic disorder with debilitating symptoms –

Andrew Peller Ltd. Announces Timing of Q1 2026 Results & Conference Call

GRIMSBY, Ontario, July 18, 2025 (GLOBE NEWSWIRE) -- Andrew Peller Limited (ADW.A / ADW.B) will issue its financial results for the three months ended June 30, 2025, after close of market on Wednesday, August 6, 2025. Management will host a conference call to discuss the financial results on Thursday, August 7, 2025, at 10:00 a.m. (ET), followed by a question-and-answer period.

Photonic Quantum Computing to Reach US$6.8 Billion by 2035 – PsiQuantum Leads as Photonic Quantum Vendors Rise

Explore the burgeoning world of Photonic Quantum Computers: these cost-effective, room-temperature machines promise significant growth, with revenues projected to soar from $1.1 billion in 2030 to $6.8 billion by 2035. Get insights on key players like PsiQuantum and market forecasts, covering vendors and components in a booming industry. 
Explore the burgeoning world of Photonic Quantum Computers: these cost-effective, room-temperature machines promise significant growth, with revenues projected to soar from $1.1 billion in 2030 to $6.8 billion by 2035. Get insights on key players like PsiQuantum and market forecasts, covering vendors and components in a booming industry.

Preservative-Free Eye Drops Market Size to reach US$1.67 billion in 2031 | CAGR of 4.3% | Exclusive Report by The Insight Partners

NEW YORK, July 18, 2025 /PRNewswire/ -- According to a new comprehensive report from The Insight Partners, the global preservative-free eye drops market is growing...

Preservative-Free Eye Drops Market Size to reach US$1.67 billion in 2031 | CAGR of 4.3% | Exclusive Report by The Insight Partners

NEW YORK, July 18, 2025 /PRNewswire/ -- According to a new comprehensive report from The Insight Partners, the global preservative-free eye drops market is growing...

Sleep Apnea Devices Market worth $11.6 billion by 2032 with 7.6% CAGR | MarketsandMarkets™

DELRAY BEACH, Fla., July 18, 2025 /PRNewswire/ -- The global Sleep Apnea Devices Market, valued at US$6.4 billion in 2024 stood at US$6.9 billion in 2025...

Technetium-99m Market Size to Reach USD 6.29 Billion by 2031, Growing at a CAGR of 3.9% | Exclusive Report by The Insight Partners

NEW YORK, July 18, 2025 /PRNewswire/ -- According to a new comprehensive report from The Insight Partners, the global technetium-99m market is witnessing substantial...

Sleep Apnea Devices Market worth $11.6 billion by 2032 with 7.6% CAGR | MarketsandMarkets™

DELRAY BEACH, Fla., July 18, 2025 /PRNewswire/ -- The global Sleep Apnea Devices Market, valued at US$6.4 billion in 2024 stood at US$6.9 billion in 2025...

Technetium-99m Market Size to Reach USD 6.29 Billion by 2031, Growing at a CAGR of 3.9% | Exclusive Report by The Insight Partners

NEW YORK, July 18, 2025 /PRNewswire/ -- According to a new comprehensive report from The Insight Partners, the global technetium-99m market is witnessing substantial...

Exosome Research Global Market Forecasts 2025-2030 | Key Market Players Paving the Way for Advancements in Exosome-Based Diagnostics and Therapeutics

The global exosome research market is anticipated to expand from USD 214.4 million in 2025 to USD 480.6 million by 2030, at a CAGR of 17.5%. This growth is driven by the rising need for advanced diagnostics due to the prevalence of chronic diseases like cancer and neurodegenerative disorders. Exosomes, serving as biomarkers and therapeutic delivery agents, fulfill this demand. The kits & reagents segment is expected to lead growth, aligning with the increased demand for efficient exosome research tools. North America is projected to experience the highest growth, thanks to significant government investments supporting research initiatives. Key players such as Thermo Fisher Scientific and Bio-Techne are profiled. 
The global exosome research market is anticipated to expand from USD 214.4 million in 2025 to USD 480.6 million by 2030, at a CAGR of 17.5%. This growth is driven by the rising need for advanced diagnostics due to the prevalence of chronic diseases like cancer and neurodegenerative disorders. Exosomes, serving as biomarkers and therapeutic delivery agents, fulfill this demand. The kits & reagents segment is expected to lead growth, aligning with the increased demand for efficient exosome research tools. North America is projected to experience the highest growth, thanks to significant government investments supporting research initiatives. Key players such as Thermo Fisher Scientific and Bio-Techne are profiled.

Muscle Gain & Strength Supplements: How CrazyBulk Muscle Building Supplements Boost Strength and Maximize Muscle Performance Fast

Explore how CrazyBulk legal muscle building supplements power muscle gain, improve muscle strength, and unlock next-level muscle performance in 2025. 
Explore how CrazyBulk legal muscle building supplements power muscle gain, improve muscle strength, and unlock next-level muscle performance in 2025.

Roundhouse Provisions Basecamp Complete Wins “Meal Replacement Product of the Year” at 2025 Mindful Awards

Plant-Based, Chuck Norris-Approved Nutrition Shake Recognized for Exceptional Convenience, Taste, and Nutritional Balance HOUSTON, July 18, 2025 /PRNewswire/ -- Roundhouse Provisions®, the trusted wellness brand...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTags6

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers